Most Read Articles
13 Jul 2019
The consumption of red and processed meats does not seem to affect the likelihood of symptom relapse among Crohn’s disease (CD) patients in relapse, reports a recent study.
Pearl Toh, 15 Jul 2019
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
15 Jul 2019
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.
Tristan Manalac, 2 days ago
In patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI), admission Killip classification and creatinine and troponin levels are important cardiac mortality predictors, according to a recent Singapore study.

Normal alanine aminotransferase protects against hepatic events in CHB patients

24 Sep 2018

In patients with chronic hepatitis B (CHB) infections on nucleos(t)ide analogue (NA) treatment, normal on-treatment alanine aminotransferase (ALT) levels are associated with lower risks of hepatic events, a recent study has shown.

Using data from the Clinical Data Analysis and Reporting System of Hong Kong, researchers evaluated serial on-treatment ALT levels of 21,182 CHB patients (mean age 51±13 years). ALT <30 and <19 U/L in males and females, respectively, were considered as normal. Composite hepatic events, including hepatocellular carcinoma, were the study outcomes.

Of the participants, 10,438 achieved normal on-treatment ALT levels within 12 months of NA treatment, while 10,745 did not. Only a minority (3.0 percent; n=627) of the patients developed the primary study outcome of composite hepatic events over a mean follow-up period of 4.0±1.7 years. Most of these were hepatocellular carcinoma (2.4 percent; n=509).

The cumulative hepatic event rates were lower in those with normal vs elevated on-treatment ALT at different time points: 3 months (4.27 percent vs 4.76 percent; p=0.083), 6 months (3.60 percent vs 5.24 percent; p<0.001), 9 months (3.44 percent vs 5.57 percent; p<0.001) and 12 months (3.51 percent vs 5.70 percent; p<0.001).

These were confirmed in fully adjusted Cox regression analyses, which showed that the risk of composite hepatic events were significantly lower in those with normal vs elevated ALT at 3 months (adjusted hazard ratio [HR], 0.61; 95 percent CI, 0.49–0.77; p<0.001), 6 months (adjusted HR, 0.55; 0.45–0.67; p<0.001), 9 months (adjusted HR, 0.54; 0.44–0.65; p<0.001) and 12 months (adjusted HR, 0.51; 0.42–0.61; p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
13 Jul 2019
The consumption of red and processed meats does not seem to affect the likelihood of symptom relapse among Crohn’s disease (CD) patients in relapse, reports a recent study.
Pearl Toh, 15 Jul 2019
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
15 Jul 2019
Fluticasone, swallowed from a multidose inhaler, and oral viscous budesonide slurry have comparable efficacies as initial treatment for eosinophilic oesophagitis, a recent study has found.
Tristan Manalac, 2 days ago
In patients with ST-segment elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (PPCI), admission Killip classification and creatinine and troponin levels are important cardiac mortality predictors, according to a recent Singapore study.